TTP is an independent technology company where scientists and engineers collaborate to invent, design and develop new products and technologies.
Joined February 2015
- Tweets 1,054
- Following 169
- Followers 1,126
- Likes 498
516 Photos and videos
Read our latest e-book, πππ ππ§πππ§π§π πππ¬π’π π§ ππ¨π« ππ¦π©π₯ππ§ππππ₯π ππππ’πππ₯ πππ―π’πππ¬ here:
Access the e-book here: eu1.hubs.ly/H0qs9_60
70
For start-ups building smart implantable devices, direct phone connectivity can be game-changing, but designing antennas that work reliably through body tissue is tough. TTPβs Biosensing team shares how we help teams solve these challenges.
eu1.hubs.ly/H0pYF100
85
Excited to share that Giles Sanders will be speaking at the Point-of-Care Testing Summit on 8β9 December.
Explore the agenda: eu1.hubs.ly/H0p-v8d0
Looking forward to connecting with partners and innovators across the diagnostics ecosystem.
31
Patient access starts long before treatment. Today, infrastructure is one of the biggest barriers to scaling advanced therapies. Our new report outlines how developers and healthcare providers can fix the bottlenecks.
Read more: eu1.hubs.ly/H0p-rmC0β¦
28
Stuart Lowe will be chairing a panel on how automation, robotics and AI are transforming ATMP manufacturing at Advanced Therapies Integrates.
Discover the actions that matter most in advanced therapy manufacturing in our Industry Agenda:
eu1.hubs.ly/H0pHt_z0
42
Implantable CGMs push BLE to its limits.
TTPβs new meandered helical antenna prototypes show reliable smartphone links are possible even with harsh 2.4 GHz tissue loss.
Read our latest e-book to dive deeper. eu1.hubs.ly/H0pYzws0
73
Bringing advanced therapies to patients isnβt just about science β itβs about implementation. For leaders across biotech and healthcare, this conversation is full of practical insight into what it takes to turn innovation into access.
π§ Listen here: eu1.hubs.ly/H0pNRph0
46
Our latest report shows how leaders across biotech, regulators and suppliers are already reimagining manufacturing systems. It sets out the 11 critical priorities that will define who can meet future patient demand.
Read it here: eu1.hubs.ly/H0pNxRR0
39
Scaling drone detection with synthetic data and edge ML
π Read the full whitepaper: eu1.hubs.ly/H0pNpWn0
#EdgeML #DroneDetection #SyntheticData #MachineLearning #CounterUAS #TechnologyInnovation #UAS
36
TTP's Stuart Lowe will chair a panel at Advanced Therapies Integrates 2025 on 2 Dec, exploring how automation, robotics & AI are transforming ATMP manufacturing.
Going? Get in touch with us to connect with Stuart whilst at the event!
eu1.hubs.ly/H0pHrGv0
1
1
50
WHITEPAPER: Low-cost handheld detection of non-cooperative UAS with edge machine learning: Pocket-sized passive RF drone detector for CUAS.
π Read it here: eu1.hubs.ly/H0pBjv60
#UAS #DroneDetection #EdgeML #SecurityInnovation #CounterUAS #Technology #MachineLearning
56
How will AI transform innovation in physical products? At #CambridgeTechWeek 2025, TTP brought together experts from Triple Chasm, CGT Catapult & Viasat to explore AIβs real-world impact β from advanced therapies to autonomous UAVs. Read the key insights: eu1.hubs.ly/H0pws-b0
51
Implant-to-smartphone via BLE is possible β but reliability, integration, and regulatory proof are tough. At TTP, validated models and cross-disciplinary expertise help de-risk development and speed up next-gen implant approvals.
Download our e-book here: eu1.hubs.ly/H0pwz_c0
45
Todayβs decisions will decide if advanced therapies stay niche or go mainstream.
Our latest report highlights 11 priorities to scale biotech and drive automation, digitalisation, and innovation.
Read it here: eu1.hubs.ly/H0pv2gp0
23
Weβre excited to be at #DubaiAirshow2025 with Speeder System π¬π§βοΈ
Visit us on the UK Pavilion, booth 435, to explore how TTP accelerates defence & aerospace innovation.
π Book a meeting: eu1.hubs.ly/H0ptJTB0
#AerospaceInnovation #DefenceTech #SpaceTec
1
76
MHRA Decentralized Manufacturing regulations came into force in the UK on 23 July β in this podcast we take a look into what this could mean for cell and gene therapies in Cambridge. ποΈ Listen here: eu1.hubs.ly/H0pmqxC0
27
The critical challenge in cell therapy isnβt whether it works β itβs whether it can be made consistently and affordably. Could concurrent engineering be the key?
Steve Taylor shares how TTP applies this approach to cell therapy manufacturing.
π eu1.hubs.ly/H0pmsWQ0
34
(2/2)As new biologics, cell, and gene therapies demand targeted and efficient delivery routes, the familiar eye drop faces new challenges. Our team explores the strengths and limitations of this most accessible route.
Find out more : ttp.com/industries/ocular-drβ¦
42